Health · 23 views
GLP-1 receptor agonist use does not increase insulin discontinuation with type 2 diabetes
For veterans with type 2 diabetes (T2D) receiving basal insulin therapy, the addition of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) does not increase the rate of insulin discontinuation compared with other glucose-lowering age…
Summary
For veterans with type 2 diabetes (T2D) receiving basal insulin therapy, the addition of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) does not increase the rate of insulin discontinuation compared with other glucose-lowering agents, according to a study published online July 14 in the Annals of Internal Medicine . Kasia J.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- An administrative gap delays access to new pancreatic cancer treatmentContinue reading
- The key to successful treatment of primary aldosteronism: Get it earlyContinue reading
- Children with cancer are being saved, but are we breaking them in the process?Continue reading
- Sitting on Japanese tatami mats may reduce anxiety and support task engagementContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow